DISOLVIDASE Hyaluronidase 1500 I.U 1x10ml (Single Vial)

Dermaqual

Aesthetic Injectable / Mesotherapy Solution

Hyaluronidase Filler Dissolver

Supplied by distributors that state products are CE Approved or CE Marked where appropriate for EU markets.
Manufactured under quality systems compliant with applicable EU cosmetic/medical device and medicinal product standards (as applicable in each jurisdiction).

Supplied by distributors that state products are CE Approved or CE Marked where appropriate for EU markets.
Manufactured under quality systems compliant with applicable EU cosmetic/medical device and medicinal product standards (as applicable in each jurisdiction).

Hyaluronidase Filler Dissolver

Description

DISOLVIDASE is a meso-lyophilised hyaluronidase preparation containing 1500 I.U of hyaluronidase in a single 10 ml vial (after reconstitution). It is a white, sterile, freeze-dried powder for solution designed as a hyaluronic acid hydrolyser. The product enzymatically cleaves hyaluronic acid polymers, accelerating the natural breakdown of hyaluronic acid and increasing tissue permeability. It is used by healthcare professionals in aesthetic practice to dissolve unwanted or mis-placed hyaluronic acid dermal fillers and to improve diffusion of other injected solutions.

Bnefits

Enzymatically digests hyaluronic acid fibres to accelerate natural breakdown of hyaluronic acid.
Dissolves unwanted or misplaced hyaluronic acid dermal fillers, helping to correct overfilling and nodules.
Increases tissue permeability and promotes the spread or dispersion of other injected solutions.
Helps manage aesthetic complications such as nodules, lumps, and localised swelling related to HA fillers.
Meso-lyophilised, sterile powder for controlled reconstitution and professional use.
Single-vial format (1500 I.U) suitable for preparing multiple small treatment aliquots under medical supervision.

Indications

Enzymatic degradation of hyaluronic acid dermal fillers when removal or reduction is desired.
Treatment of unwanted aesthetic outcomes from hyaluronic acid fillers such as nodules, lumps or localised over-correction.
Supportive use in managing tissue ischaemia or compromised perfusion associated with hyaluronic acid filler deposits, in accordance with clinical guidelines and local protocols.
Adjunct to mesotherapy protocols where increased tissue permeability for other injected solutions containing hyaluronic acid is indicated, as determined by a qualified healthcare professional.
Adjunctive treatment of cellulite appearance in some body-contouring protocols, as part of professional aesthetic regimens.

Composition

Hyaluronidase 1500 I.U (per vial, lyophilised powder)
Aqua / Water (after reconstitution)
Mannitol
Other excipients as per manufacturer’s specification

Formulation

White, sterile, freeze-dried (meso-lyophilised) powder for solution for injection / mesotherapy in a 10 ml vial.
Intended to be reconstituted with injectable saline to obtain a 10 ml solution containing 1500 I.U hyaluronidase (150 I.U per ml).

Packaging

Single sterile glass vial containing 1500 I.U hyaluronidase (lyophilised powder) nominally for 10 ml solution after reconstitution.
Outer carton with vial and package insert (content details may vary by market).

Usage

For professional use only by appropriately qualified healthcare practitioners experienced in the use of hyaluronidase and the management of dermal filler complications.
Reconstitute the lyophilised powder with injectable (physiological) saline in accordance with the manufacturer’s instructions to obtain a total volume of 10 ml solution (150 I.U per ml).
Use strict aseptic technique during reconstitution and administration.
Administer only to appropriate treatment areas and indications as determined by clinical assessment (e.g. areas with unwanted hyaluronic acid filler or selected cellulite treatment areas).
Do not mix in the same syringe with other active substances; if used alongside other products, administer separately according to professional judgement.
Single-patient use; discard any unused reconstituted solution in line with local regulations and manufacturer guidance.
The product is a prescription-only medicine in many jurisdictions; local legislation and professional guidelines must be followed.

Contraindications

Known hypersensitivity or allergy to hyaluronidase or any of the excipients.
History of severe allergic reactions to bee stings or bovine-derived collagen (due to potential cross-reactivity with hyaluronidase preparations).
Active or infected skin lesions at the proposed treatment site.
Children, pregnant women and breastfeeding women (use not recommended).
Use in conjunction with laser, chemical peel or dermabrasion treatments in the same area at the same time (as per manufacturer and distributor warnings).

Adverse Effects

Local injection site reactions such as redness (erythema), swelling, pain, burning or itching.
Bruising or haematoma at the injection site.
Transient oedema related to enzymatic degradation of hyaluronic acid.
Rare allergic or hypersensitivity reactions including urticaria, angioedema or, very rarely, anaphylaxis.
Over-correction or excessive dissolution of desirable hyaluronic acid filler if dosing or placement is inappropriate.
Any other adverse events associated with invasive aesthetic procedures (e.g. infection, vascular compromise) if technique or indication is inappropriate.

Storage Conditions

Store unopened vials in a cool, dry place, at controlled room temperature as indicated on the product packaging.
Keep away from direct heat and sunlight.
Keep out of the reach of children.
Use within the expiry date printed on the vial and outer carton.
After reconstitution, use immediately or within the time frame specified by the manufacturer; discard any unused solution according to local regulations.

Duration

Determined by the treating healthcare professional based on clinical indication; typically involves a single treatment session or a short series of sessions until the desired reduction of hyaluronic acid filler or clinical effect is achieved.

Onset

Not explicitly specified by the manufacturer; clinically, hyaluronidase generally begins to act rapidly after administration, with progressive softening and reduction of hyaluronic acid filler over hours to days.